Skye Bioscience, Inc. (SKYE)
NASDAQ: SKYE · Real-Time Price · USD
1.200
-0.010 (-0.83%)
Dec 5, 2025, 4:00 PM EST - Market closed
Skye Bioscience Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 15.25 | 11.49 | 7.7 | 12.3 | 4.92 | 4.34 | |
| Research & Development | 38.69 | 18.7 | 5.82 | 6.01 | 2.93 | 1.94 | |
| Other Operating Expenses | 0 | 0 | -0 | - | - | - | |
| Operating Expenses | 53.94 | 30.19 | 13.52 | 18.31 | 7.85 | 6.29 | |
| Operating Income | -53.94 | -30.19 | -13.52 | -18.31 | -7.85 | -6.29 | |
| Interest Expense | - | -0.75 | -0.91 | -0.67 | -0.77 | -0.71 | |
| Interest & Investment Income | 2.39 | 3.03 | 0.1 | 0.02 | 0 | 0 | |
| Other Non Operating Income (Expenses) | 0 | - | - | -0.06 | -0.02 | 0.44 | |
| EBT Excluding Unusual Items | -51.55 | -27.92 | -14.33 | -19.02 | -8.64 | -6.56 | |
| Gain (Loss) on Sale of Assets | 0.32 | 1.36 | -0.31 | - | - | - | |
| Asset Writedown | - | - | -0.41 | -0.46 | - | - | |
| Other Unusual Items | - | - | -1.38 | - | 0.12 | - | |
| Pretax Income | -51.22 | -26.56 | -37.64 | -19.47 | -8.52 | -6.56 | |
| Income Tax Expense | 0.01 | 0.01 | 0 | 0.01 | 0 | 0 | |
| Net Income | -51.23 | -26.57 | -37.64 | -19.48 | -8.52 | -6.56 | |
| Net Income to Common | -51.23 | -26.57 | -37.64 | -19.48 | -8.52 | -6.56 | |
| Shares Outstanding (Basic) | 40 | 36 | 7 | 2 | 2 | 1 | |
| Shares Outstanding (Diluted) | 40 | 36 | 7 | 2 | 2 | 1 | |
| Shares Change (YoY) | 34.31% | 420.79% | 215.43% | 36.56% | 75.70% | 36.48% | |
| EPS (Basic) | -1.29 | -0.73 | -5.37 | -8.77 | -5.24 | -7.11 | |
| EPS (Diluted) | -1.29 | -0.73 | -5.37 | -8.77 | -5.24 | -7.46 | |
| Free Cash Flow | -41.53 | -26.84 | -13.96 | -12.84 | -6.57 | -6.06 | |
| Free Cash Flow Per Share | -1.04 | -0.74 | -1.99 | -5.78 | -4.04 | -6.55 | |
| EBITDA | -53.22 | -29.9 | -13.4 | -18.2 | -7.81 | -6.29 | |
| D&A For EBITDA | 0.72 | 0.3 | 0.12 | 0.11 | 0.03 | 0 | |
| EBIT | -53.94 | -30.19 | -13.52 | -18.31 | -7.85 | -6.29 | |
Source: S&P Capital IQ. Standard template.
Financial Sources.